Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2587 - Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study of the EAU-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration

Date

10 Sep 2017

Session

Poster display session

Presenters

Andrea Necchi

Citation

Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371

Authors

A. Necchi1, S. Lo Vullo2, L. Mariani2, M. Moschini3, K. Hendricksen4, M. Rink5, R. Sosnowski6, J. Dobruch7, J.D. Raman8, C.G. Wood9, V. Margulis10, M. Rouprêt11, A. Briganti12, F. Montorsi13, E. Xylinas14, S.F. Shariat15

Author affiliations

  • 1 Medical Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 2 Clinical Epidemiologi And Trials Organization Unit, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 3 Department Of Urology, Luzerner Kantonsspital, Luzern/CH
  • 4 Urology, The Netherlands Cancer Institute, Amsterdam/NL
  • 5 Urology, Universitätsklinikum Hamburg, Eppendorf/DE
  • 6 Urology, European Health Centre, Otwock/PL
  • 7 Urology, M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw/PL
  • 8 Urology, Penn State Health Milton S. Hershey Medical Center, Hershey/US
  • 9 Urology, UT M.D. Anderson Cancer Center, Houston/US
  • 10 Urology, UT Southwestern Medical Center, Dallas/US
  • 11 Urology, Pitié-Salpêtrière Hospital, 75651 - Paris/FR
  • 12 Urology, Vita Salute San Raffaele University, Milano/IT
  • 13 Urology, IRCCS San Raffaele, 20132 - Milan/IT
  • 14 Urology, Cochin Hospital, Assistance-Publique Hôpitaux de Paris, Paris/FR
  • 15 Urology, Medical University of Vienna, Vienna/AT
More

Resources

Abstract 2587

Background

In patients (pts) with upper tract urothelial carcinoma (UTUC) the benefit of adjuvant chemotherapy (ACT) after radical nephroureterectomy (RNU) is debated. We aimed to analyze the benefit of ACT vs observation (Obs) in an international study.

Methods

Data from 15 centers was collected, totalling 1,544 pts, treated between 2000 and 2015. Criteria for pt selection were: UTUC diagnosis, pT2-4N0/x and/or pN+ stage undergoing RNU. The standardized differences (SD) approach was used to compare subgroup characteristics. Overall survival (OS) was the primary endpoint. The adopted propensity scores (PS) techniques included 1:1 PS matching and inverse probability of treatment weighting (IPTW). Additionally, the IPTW analysis was performed with the inclusion of the covariates, i.e. with doubly robust estimation (DREP). 6-month landmark analysis (LA) was also performed.

Results

A total of 312 pts received ACT and 1,232 observations. Despite differences between the two groups, SD was generally

Conclusions

ACT does not improve OS compared to Obs in pT2-4 and/or pN+ UTUC. These findings contribute to the uncertainties regarding ACT in UTUC and further support the need for dedicated prospective trials in UTUC, new more potent therapies, and enhanced pt selection criteria.

Clinical trial identification

Legal entity responsible for the study

Andrea Necchi

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.